Trial Profile
A prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Progressive Supranuclear Palsy (PSP)
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 25 May 2018
Price :
$35
*
At a glance
- Drugs Masitinib (Primary)
- Indications Progressive supranuclear palsy
- Focus Therapeutic Use
- Sponsors AB Science
- 19 May 2018 Status changed from recruiting to discontinued.
- 02 Jul 2015 New trial record